Sector Data Insights (SDI) is a specialized market intelligence and strategic consulting firm focused on delivering high-quality, data-driven syndicated research reports, industry analysis, competitive intelligence, and advisory solutions. With a strong emphasis on analytical excellence, particularly in life sciences, analytical instrumentation, and related high-tech sectors, Sector Data Insights empowers manufacturers, investors, service providers, researchers, and decision-makers with actionable insights for strategic growth, innovation, and market leadership.
SDI combines deep domain expertise in laboratory and analytical technologies with advanced analytics to provide comprehensive market assessments, technology trend analysis, vendor share data, investment intelligence, supply chain insights, and forward-looking forecasts. Our research supports organizations navigating complex global markets across industries such as life sciences, semiconductors & electronics, consumer goods, materials & chemicals, construction & manufacturing, food & beverages, energy & power, automotive & transportation, ICT & media, aerospace & defense, and BFSI.
+1 2315155523
Sakshi Gurunule
Research Associate


| Year | Market Size |
|---|---|
| 2024 | 6.620 B |
| 2025 | 7.300 B |
| 2026 | 8.060 B |
| 2027 | 8.900 B |
| 2028 | 9.820 B |
| 2029 | 10.84 B |
| 2030 | 11.80 B |
The Europe powder dietary supplements market comprises free-flowing, mixable nutritional products—protein, amino acid, vitamin, botanical and multivitamin blends—sold in pouches, tubs and sachets for mixing into liquids. It serves sports nutrition, general wellness, weight management and prescribed clinical nutrition across EU-27 plus the UK, Norway and Switzerland.
This analysis covers powder-format dietary supplements sold through OTC, pharmacy, specialty retail and e-commerce channels across Europe including the UK, Germany, France, Italy, Spain, Russia, Poland and the Netherlands. It includes ingredient-level segmentation (vitamins, proteins, botanicals, multivitamins) and end-user splits. This analysis does not cover capsules, tablets, gummies, liquids, fortified foods, sports beverages, or medical foods requiring prescription-only classification.
The market was estimated at USD 6.62 billion in 2024, with forecasts diverging sharply on horizon length: near-term projections point to USD 11.8 billion by 2030, while extended forecasts reach USD 19.2-19.3 billion by 2035.
| Estimate | Base Year | Horizon | CAGR | Definition / Scope | Attribution |
|---|---|---|---|---|---|
| USD 6.62 Billion | 2024 | 2030 | 10.4% | Powder-format dietary supplements, all channels, EU+UK | One published estimate |
| USD 7.3 Billion | 2025 | 2035 | 10.2% | Same scope, broader 10-year horizon | A competing analysis |
| USD 11.8 Billion | 2030 | 2030 | 10.4% | Mid-point projection | Derived from base + CAGR |
Our analysis suggests the 2024 base of USD 6.62 billion is the most defensible starting point because it aligns with broader dietary supplement benchmarks, where powder formats represent roughly 13-14% of the total European supplements market (USD 48.88 billion in 2025). The 2035 figure of USD 19.2 billion implies near-tripling over a decade, which is plausible only if personalized nutrition and clinical powder adoption accelerate beyond current trajectory.
The market segments by ingredient, type, application, end-user and distribution channel, with proteins and OTC formats dominating current revenue.
| Parent Segment | Children |
|---|---|
| By Ingredient | Vitamins, Multivitamins, Proteins & Amino Acids, Botanicals, Minerals |
| By Type | OTC, Prescribed |
| By Application | Sports Nutrition, General Wellness, Weight Management, Clinical Nutrition |
| By End-User | Adults, Elderly, Children, Athletes |
| By Distribution Channel | Pharmacies, Specialty Stores, E-commerce, Supermarkets |
Proteins command 42.8% of ingredient share according to one analysis, while vitamins lead a competing estimate at 28.07%—a divergence that reflects differing classification of multivitamin blends. Sports nutrition accounts for 38.6% of application share and adults represent 62.4% of end-users.
Germany leads with 25.0% regional revenue share, anchored by its mature pharmacy network and high health literacy, while Poland posts the fastest growth at 11.2% CAGR.
Our analysis suggests the Eastern European cluster (Poland, Romania, Czechia) will contribute disproportionately to incremental volume through 2030, as disposable income converges with Western levels and gym penetration rises from a low base.
Fitness consciousness, clean-label demand and e-commerce expansion are the primary growth engines, while fragmented national regulations and EFSA health-claim scrutiny restrain faster adoption.
| Factor | Direction | Evidence Strength | Mechanism |
|---|---|---|---|
| Rising fitness and sports participation | Driver | High | Protein and BCAA powder demand among younger demographics |
| Clean-label and plant-based preference | Driver | High | Vegan protein and botanical blends; transparency scrutiny |
| E-commerce and D2C expansion | Driver | High | Online supplement sales ~18% CAGR (2020-2024) |
| Aging population and clinical nutrition | Driver | Medium | Prescribed powders at 10.8% CAGR; 22% of Europeans aged 65+ |
| Fragmented country-level regulation | Restraint | High | Complex product registration and labeling across EU-27 |
| EFSA health-claim scrutiny | Restraint | Medium | Limits marketing claims; raises compliance costs |
| Counterfeit and quality concerns | Restraint | Medium | Undermines trust in unbranded online channels |
The balance favors growth: drivers carry high evidence strength across multiple independent benchmarks, whereas restraints are structural but manageable through compliance investment. Our analysis suggests the regulatory burden actually advantages established brands with in-house regulatory affairs, creating a moat against smaller entrants.
Glanbia, Optimum Nutrition, Dymatize, BSN and MuscleTech lead sports nutrition powders, while Bayer, Haleon and Procter & Gamble dominate broader wellness formats.
| Company | Primary Focus | Competitive Moat |
|---|---|---|
| Glanbia Plc | Protein and performance nutrition | Vertical integration in dairy protein; global brand portfolio |
| Optimum Nutrition | Sports nutrition powders | Brand loyalty and athlete endorsement |
| Dymatize Nutrition | Protein and amino acid powders | Hydrolyzed protein technology and bioavailability |
| BSN | Sports nutrition blends | Flavor innovation and mass-channel distribution |
| MuscleTech | Performance powders | Premium positioning and clinical backing |
| Bayer AG | Vitamins and general wellness | Pharmacy reach and regulatory affairs |
| Haleon plc | Multivitamins and minerals | Consumer trust and pan-European distribution |
Differentiation hinges on protein sourcing, flavor technology and clinical substantiation. Our analysis suggests the strongest moat belongs to vertically integrated protein suppliers such as Glanbia, which control raw material costs and can defend margins as whey and pea protein prices fluctuate.
Procurement decisions in this market hinge on three mission-critical criteria: ingredient traceability, EFSA-compliant claim substantiation, and cold-chain or shelf-stability guarantees for protein and probiotic blends. Buyers should prioritize suppliers with documented third-party testing and organic or non-GMO certification, as clean-label scrutiny intensifies. Switching costs are moderate but rise sharply for clinically positioned products requiring dossier continuity. Regulatory risk is concentrated in health-claim approval timelines, which vary by member state despite Directive 2002/46/EC harmonization. Operators should also model currency exposure on whey and pea protein, where price volatility can erode 200-400 basis points of margin. Finally, e-commerce channel conflict is a growing procurement concern, as D2C brands undercut pharmacy pricing and complicate MAP enforcement.
The balance of evidence favors a protein-led, compliance-moated growth thesis. The convergence of 10.2-10.4% CAGR across independent forecasts, protein's 42.8% ingredient share and sports nutrition's 38.6% application share creates a durable demand core. The strongest counter-argument is that the 2035 forecasts (USD 19.2 billion) may overstate growth if European fitness participation plateaus and EFSA restricts protein-health claims; a more conservative USD 15-16 billion by 2035 is defensible.
Our analysis suggests the most underappreciated opportunity lies in prescribed clinical nutrition powders, growing at 10.8% CAGR and insulated from fitness-cycle volatility by aging demographics. Vendors that bridge sports nutrition brand equity with clinical credibility—through pharmacy-channel medical nutrition lines—will capture the most resilient margin pool.
Actionable Strategy:
The evidence that would change our conclusion: a sustained EFSA ruling restricting protein or amino acid health claims, or a structural decline in European gym membership, would shift the risk-reward toward clinical and senior-nutrition segments.
| Region | Market Share (%) |
|---|---|
| Germany | 0.25% |
| United Kingdom | 0.18% |
| France | 0.15% |
| Italy | 0.12% |
| Russia | 0.1% |
| Spain | 0.08% |
| Poland | 0.06% |
| Netherlands | 0.05% |
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 10.4% from 2020-2034 |
| Segmentation |
|
The market was estimated at USD 6.62 billion in 2024 and is forecast to reach USD 11.8 billion by 2030, growing at a 10.4% CAGR. Extended forecasts project USD 19.2-19.3 billion by 2035.
Proteins hold the largest share at 42.8% according to one analysis, with vitamins leading a competing estimate at 28.07%. Proteins and amino acids are also the fastest-growing ingredient class at 14.6% CAGR through 2030.
Germany leads with 25.0% regional revenue share, supported by approximately 18,000 pharmacies and high health literacy. The UK follows at 18.4%, France at 14.6% and Italy at 12.3%.
Poland posts the highest growth at 11.2% CAGR, driven by fitness development and rising athletic awareness. The broader Eastern European cluster is expected to contribute disproportionately to incremental volume through 2030.
Key trends include plant-based and vegan protein powders, clean-label formulations, personalized nutrition, e-commerce and D2C expansion, and growth in prescribed clinical nutrition powders targeting aging populations.
Leading companies include Glanbia Plc, Optimum Nutrition, Dymatize Nutrition, BSN and MuscleTech in sports nutrition, alongside Bayer AG, Haleon plc and Procter & Gamble in broader wellness and vitamin powder formats.
Forecasts project 10.2-10.4% CAGR through 2030-2035, with the market reaching USD 11.8 billion by 2030 and USD 19.2-19.3 billion by 2035, driven by fitness, clean-label and clinical nutrition demand.
Fragmented country-level regulations, EFSA health-claim scrutiny, counterfeit concerns and raw material price volatility in whey and pea protein are the primary challenges restraining faster growth.
Our rigorous research methodology combines multi-layered approaches with comprehensive quality assurance, ensuring precision, accuracy, and reliability in every market analysis.
This study employed a 70/30 primary-to-secondary research split, with in-depth interviews conducted across the value chain: raw material and protein suppliers, specialized powder formulators and blenders, contract manufacturers, and pan-European distributors. Decision-makers interviewed included VP-level Sourcing leads, Heads of R&D and Formulation, Technical Directors, and Commercial Operations Leads. Interviews probed capacity utilization, formulation trends, pricing structures and channel strategy.

| Stakeholder Role | Interview Share (%) |
|---|---|
| R&D & Formulation Heads | 40% |
| Procurement & Sourcing Leads | 35% |
| Quality & Regulatory Leads | 25% |

| Company Type | Representation (%) |
|---|---|
| Raw Material & Protein Suppliers | 45% |
| Specialized Formulators & Blenders | 35% |
| Distributors & Traders | 20% |
Secondary validation drew on Eurostat trade databases, UN Comtrade protein and supplement flows, WTO tariff schedules, corporate annual filings and investor presentations, patent databases for protein and bioavailability technologies, and EFSA published health-claim opinions and Directive 2002/46/EC documentation.
Simultaneous top-down macroeconomic and segment-allocation modeling was combined with bottom-up manufacturer capacity, product pricing and end-use consumption modeling. Cross-validation reconciled divergent ingredient share estimates (proteins at 42.8% vs vitamins at 28.07%) by normalizing classification boundaries.
| Dimension | Analytical Scope | Methodology Applied | Validation Level |
|---|---|---|---|
| Base-Year Market Size | Value in USD for base year | Bottom-up production & revenue triangulation | High |
| Forecast Horizon | Multi-year compound projection | Historical CAGR, regression analysis & demand elasticity | High |
| Regional Distribution | Regional share breakdown | Cross-border trade flow analysis & regional consumption | High |
| Competitive Landscape | Leading market players | Annual reports, capacity mapping & commercial filings | High |